TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01957930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensified insulin treatment
Description: The treatment regimen of the intensified treatment group consisted of individual education and then continuous tutoring with frequent face-to-face and telephone contact.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Patients continuing with routine diabetes care (insulin treatment), visiting physician every four months
Study: NCT01605162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: TMZ (at 150 mg/m2) will be administered orally according to the instructions on the product label, on Days 1 through 5 of the same 28-day cycle as E7016. TMZ capsules should be taken immediately after E7016. No food or drink intake, except water, will be allowed for 2 hours before or after administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7016
Description: E7016 capsules will be administered in the morning after at least a 2-hour fast. Subjects will be instructed not to eat or drink anything except water in the 2 hours prior and 2 hours after drug administration. Subjects will record the time at which they ate.~For the Single-Dose PK Period, 320 mg of E7016 will be administered once on Day -2. For the Multiple-Dose Treatment Cycle(s), 320 mg E7016 will be administered QD on Days 1 through 7 of each 28-day cycle.
Study: NCT04154735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: A chemotherapy medication commonly used in the treatment of leukemia and lymphoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A medication used as chemotherapy and to suppress the immune system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: A protein that kills the immune cells that are thought to be causing Crohn's; it is commonly used in the treatment of leukemia and lymphoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: An antibiotic used to treat irritable bowel syndrome and relapsing C. difficile infection; it inhibits DNA-dependent RNA polymerase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: A medication which suppresses the immune system and inhibits T-lymphocytes; commonly used to lower the risk of organ rejection following transplant
Study: NCT03166384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrosurgical bipolar sealing devices
Description: Electrosurgical bipolar sealing devices use the body's own collagen and elastin to create a permanent fusion zone through a combination of pressure and energy. Previous studies suggested that surgery using these devices lead to significant decrease of seroma formation, however their advantages are not well established in case of mastectomy for breast cancer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional suture and tie
Description: the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.
Study: NCT02641808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: follicular flushing
Description: Depending on randomisation the follicle is not flushed (group A) or flushed adapted to follicule size (16mm 2ml, 18mm 3ml, and 20mm 4ml etc.) up to five times with (e.g.flushing media with heparin (SynVitro® Flush, Origio, Berlin, Germany). The flushings are collected each in a separate collecting tube (group B). The analysis of the collected oocytes is performed in the IVF lab.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no follicular flushing
Study: NCT02159417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Education
Description: Realization of a consultation of educational diagnosis, followed by the participation for every patient to 4 educational collective workshops therapeutic:~* Knowledge of the disease~* Food~* Physical Activity and care of feet~* The therapeutics
Study: NCT02836730

Intervention type: PROCEDURE
Intervention: Low back pain surgery

Intervention type: PROCEDURE
Intervention: Low back pain surgery

Intervention type: PROCEDURE
Intervention: Low back pain surgery
Study: NCT00386178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E supplement rich in gamma tocopherol
Description: daily dose of Vitamin E supplement rich in gamma tocopherol
Study: NCT03262909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GelrinC
Description: Patients will undergo GelrinC implantation.

Intervention type: OTHER
Group type: OTHER
Intervention: Microfracture historical control arm
Description: Patients undergo an arthroscopy for evaluation purposes, followed by lesion debridement, and a standard microfracture procedure.
Study: NCT01583491

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous platlet rich fibrin
Description: one dose immediate after surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: one side in control group
Description: control group insert any things after surgery
Study: NCT03290872

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carpentier Edwards Physio 2 Complete flexible mitral ring
Description: Mitral valve Annuloplasty Ring repair using a Carpentier Edwards Physio 2 Complete flexible mitral ring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Simplici T Partial flexible mitral annuloplasty ring
Description: Mitral valve Annuloplasty Ring repair using a Simplici T Partial flexible mitral annuloplasty ring
Study: NCT01844518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abatacept
Study: NCT01399515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid
Description: One 500mg tablet by mouth daily
Study: NCT02157987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacuzimab spray
Study: NCT02600572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercises
Description: Subjects will perform one session of isometric exercises at the end of Day 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercises
Description: Subjects will perform one session of eccentric exercises at the end of Day 2
Study: NCT01496612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01646723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteers Adding Life in Dementia (VALID) Program
Description: The VALID intervention will consist of 2 phases. First, volunteers will complete an assessment involving recording of a Life Story for each patient participant. This will include information on the patient's psychosocial history, occupational history, hobbies, interests and preferred activities using information from the LTC medical record and interviews with the patient and family members. Based on this information, a variety of potential psychosocial interventions will be developed for the individual with the assistance of the recreation therapist at the LTC. The second phase will involve implementation of the VALID intervention. Each individual with dementia will receive personalized pleasant activities for a minimum session of 30 minutes at a frequency of 3 times per week. One volunteer will complete the Life Story assessment and up to 3 volunteers may be involved with implementing the VALID program for each resident.
Study: NCT01458938

Intervention type: OTHER
Intervention: treatment plan
Description: Data Collection Study

Intervention type: OTHER
Intervention: treatment plan
Description: Data Collection Study

Intervention type: OTHER
Intervention: treatment plan
Description: Data Collection Study
Study: NCT04317469

Intervention type: DIAGNOSTIC_TEST
Intervention: VWF measurement
Description: Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).

Intervention type: DIAGNOSTIC_TEST
Intervention: VWF measurement
Description: Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).
Study: NCT03989271

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Quercetin
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin
Description: Placebo
Study: NCT01678430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Study: NCT02818400

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: composite tissue allotransplantation
Study: NCT01927172

Intervention type: DEVICE
Group type: OTHER
Intervention: AirSonea
Study: NCT03995186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural activation
Description: 4-week programme based on the behavioural activation treatment provided in the NHS IAPT services. The programme includes psychoeducation on the relationship between activity and depression, examining the depressed person's level of activity, helping them identify activities they would like to increase and supporting them in the planning and conduct of those activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity monitoring
Description: 4-week programme where participants simply monitor their general daily activities in a diary.
Study: NCT04600102

Intervention type: DEVICE
Intervention: Structure Sensor
Description: A 3D representation of each participant's lower limb geometry will be obtained using a Structure Sensor scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.

Intervention type: DEVICE
Intervention: Structure Sensor
Description: A 3D representation of each participant's lower limb geometry will be obtained using a Structure Sensor scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
Study: NCT04505748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-transfusion device
Description: The Transfusion filter set for salvaged blood (Summit Medical Ltd, Gloucestershire, UK) has been randomly used in 20 patients postoperatively. Patients, who received autologous blood, transfused with the collected amount of blood, only once, 6h postoperatively
Study: NCT03002129

Intervention type: OTHER
Group type: OTHER
Intervention: fluid challenge
Description: At two pre-defined time points during the procedure, enrolled patients will receive a fluid bolus of 5 ml/kg during 5 minutes
Study: NCT02281292

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LKA651 ophthalmic solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LKA651 ophthalmic solution
Study: NCT01639300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNbAC1
Description: Single dose intravenous (IV) GNbAC1 2mg/kg or 6mg/kg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GNbAC1 placebo
Description: Single dose intravenous (IV) GNbAC1 placebo
Study: NCT00776373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin + high dose etoposide and cytarabine
Description: Rapamycin,by mouth, loading dose followed by a single daily dose for 8 days (dose level 1 = load of 9 mg followed by 3 mg daily doses, dose level 2 = 12 mg with daily doses of 4 mg; Etoposide 500 mg/m2/day IV and Cytarabine 2000 mg/m2/day IV every 24 hours for 4 days.
Study: NCT00086385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine polacrilex, Bupropion
Description: Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex, Bupropion
Description: Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex, Bupropion
Description: Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex, Bupropion
Description: Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.
Study: NCT04613271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 500 mg once a day for 5 days.
Study: NCT03624439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard double-lumen tube
Description: intubation using standard double-lumen tube with Macintosh laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard double-lumen tube
Description: intubation using standard double-lumen tube with Macintosh laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double-Lumen Tube Vivasight-DL
Description: intubation using Double-Lumen Video Tube Vivasight-DL with Macintosh laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double-Lumen Tube Vivasight-DL
Description: intubation using Double-Lumen Video Tube Vivasight-DL with Macintosh laryngoscope
Study: NCT00429572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenously Daily for 5 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m\^2 intravenously Daily for 2 Days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Stem Cell Infusion on Day 0.
Study: NCT01953367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vantobra (tobramycin)
Description: Inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TOBI (tobramycin)
Description: Inhalation
Study: NCT02428933

Intervention type: DRUG
Group type: OTHER
Intervention: Bromocriptine
Description: The investigators will look at the physiological effect of dopamine on BAT activity rather than on the effect of the drug itself
Study: NCT03372447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg
Description: Single intramuscular dose of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg.
Study: NCT05299645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interview
Description: Pilot study with digital browsers
Study: NCT01222897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir hydrochloride
Study: NCT03870906

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Occupational-specific health talk
Description: Health talk will provide information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational-specific health talk
Description: Health talk will provide information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp interaction
Description: Individual WhatsApp interactions last 3-month and consist of 2 parts. First part is regular WhatsApp message. The schedule will be adjusted according to the participants' quitting status. Second part is real-time discussion intervention based on participants' socio-demographic characteristics, smoking habit at baseline and updated smoking status obtained during online conversation. At 3-month follow-up, participants who are still smoking are encouraged to join an additional 1-month online group chat moderated by a smoking cessation counselor.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Phone follow-up/counselling service
Description: The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone follow-up/counselling service
Description: The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Text message
Description: Participants will receive regular text messages with similar frequency to those in the intervention group.
Study: NCT02606344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mico-finance based intervention
Study: NCT01712490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Doxorubicin: 25 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: Doxorubicin: 25 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bleomycin
Description: Bleomycin: 10 units/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
Study: NCT02281292

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ranibizumab ophthalmic solution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ranibizumab ophthalmic solution
Study: NCT02223832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-128800
Study: NCT01712490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinblastine
Description: Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: Dacarbazine (DTIC): 375 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine
Description: Dacarbazine (DTIC): 375 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
Study: NCT01820494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Infant formula to be fed ad libitum
Study: NCT03157336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Inferiority WTM Interventional Trial
Description: The intervention will implement the WTM cassava processing technique in participating households. Twenty women (in leading roles) will be our principal candidates to serve as peer trainers. Together with a 20 community health worker specialists, these women will be trained in the WTM technique by the Kinshasa team of community health workers who are experts in the WTM method. Those who master the technique will then be certified as trainers to train and support other small groups of other mothers throughout a two-year period in the implementation of the WTM for the safer processing of food for their families. Both the community health worker specialists and trained women (prospective trainers) would have to be able to bring the cassava cyanogenic content to the lowest achievable level, which must be \< 10 ppm as per the recommendations of the World Health Organization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Inferiority WTM Interventional Trial
Description: The intervention will implement the WTM cassava processing technique in participating households. Twenty women (in leading roles) will be our principal candidates to serve as peer trainers. Together with a 20 community health worker specialists, these women will be trained in the WTM technique by the Kinshasa team of community health workers who are experts in the WTM method. Those who master the technique will then be certified as trainers to train and support other small groups of other mothers throughout a two-year period in the implementation of the WTM for the safer processing of food for their families. Both the community health worker specialists and trained women (prospective trainers) would have to be able to bring the cassava cyanogenic content to the lowest achievable level, which must be \< 10 ppm as per the recommendations of the World Health Organization.
Study: NCT01866813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training intervention group
Description: The intervention group will be asked to participate in an internet-delivered cognitive training pro-gram using the Danish edition of Scientific Brain Training Pro on their home personal computer. The software is provided through the Internet, and no software installation is needed onto the participant personal computer. Reminders to train will be provided by e-mail. The training involves working with the program for 40-60 minutes a day, five days a week, for six weeks.
Study: NCT03619850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
Study: NCT03085381

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo